Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-6 in Allergic Contact Dermatitis
NCT00867607Phase 2Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Mar 2011
- Primary completion
- Apr 2013
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of EB02 in allergic contact dermatitis (ACD), sponsored by Hadassah Medical Organization. Started Mar 2011; status: completed.
02
Drugs
EB02
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT00867607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00867607.